A multistep validation process of biomarkers for preclinical drug development

被引：0
作者：
W M Freeman
G V Bixler
R M Brucklacher
C-M Lin
K M Patel
H D VanGuilder
K F LaNoue
S R Kimball
A J Barber
D A Antonetti
T W Gardner
S K Bronson
机构：
[1] Functional Genomics Core Facility,Department of Pharmacology
[2] Penn State College of Medicine,Department of Cellular & Molecular Physiology
[3] Penn State College of Medicine,Department of Ophthalmology
[4] Penn State College of Medicine,undefined
[5] Penn State College of Medicine,undefined
来源：
The Pharmacogenomics Journal | 2010年 / 10卷
关键词：
biomarker; drug development; preclinical; gene expression; diabetic retinopathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Biomarkers that can be measured in preclinical models in a high-throughput, reproducible manner offer the potential to increase the speed and efficacy of drug development. Development of therapeutic agents for many conditions is hampered by the limited number of validated preclinical biomarkers available to gauge pharmacoefficacy and disease progression, but the validation process for preclinical biomarkers has received limited attention. This report defines a five-step preclinical biomarker validation process and applies the process to a case study of diabetic retinopathy. By showing that a gene expression panel is highly reproducible, coincides with disease manifestation, accurately classifies individual animals and identifies animals treated with a known therapeutic agent, a biomarker panel can be considered validated. This particular biomarker panel consisting of 14 genes (C1inh, C1s, Carhsp1, Chi3l1, Gat3, Gbp2, Hspb1, Icam1, Jak3, Kcne2, Lama5, Lgals3, Nppa, Timp1) can be used in diabetic retinopathy pharmacotherapeutic research, and the biomarker development process outlined here is applicable to drug development efforts for other diseases.
引用
收藏
页码：385 / 395
页数：10
相关论文
共 178 条
[1]  
Lewin DA(2004)Molecular biomarkers in drug development Drug Discov Today 9 976-983
[2]  
Weiner MP(2005)How molecular profiling could revolutionize drug discovery Nat Rev Drug Discov 4 345-350
[3]  
Stoughton RB(2004)Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3 711-715
[4]  
Friend SH(2001)Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 89-95
[5]  
Kola I(2006)A cost-effectiveness approach to the qualification and acceptance of biomarkers Nat Rev Drug Discov 5 897-902
[6]  
Landis J(2003)Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development Clin Pharmacol Ther 73 284-291
[7]  
Williams SA(2001)Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies Annu Rev Pharmacol Toxicol 41 347-366
[8]  
Slavin DE(2003)Prediction of clinical drug efficacy by classification of drug-induced genomic expression profiles Proc Natl Acad Sci USA 100 9608-9613
[9]  
Wagner JA(2005)A quantitative genomic expression analysis platform for multiplexed Pharmacogenomics J 5 126-134
[10]  
Webster CJ(2008) prediction of drug action Bioinformatics 24 389-395
12345678910